HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing.
With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow.
The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery.
This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment.
To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards.
François Fournier, CEO of HTL Biotechnology, states: "I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction."
As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France.
About HTL
HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide.
To learn more about HTL Biotechnology: https://htlbiotech.com/
LinkedIn: HTL Biotechnology
X: @HTL_Biotech
Instagram: @htlbiotechnology
Press contact
Nathalie Chevallon - HTL Biotechnologynchevallon@htlbiotech.com
View original content:https://www.prnewswire.com/apac/news-releases/htl-biotechnology-inaugurates-a-new-production-line-dedicated-to-sterile-hyaluronic-acid-302474560.html
SOURCE HTL Biotechnology

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

17 minutes ago

• Yahoo

The 5 Most Interesting Analyst Questions From Merck's Q1 Earnings Call

Merck's first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% year-over-year revenue decline. Management identified continued strength in the oncology portfolio, especially KEYTRUDA and Welireg, alongside growth from new product launches like WinRevair and Cafaxib, as pivotal to performance. CEO Rob Davis cited 'increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline.' Merck also managed through significant declines in Gardasil sales in China, emphasizing that underlying global demand outside China remained robust. Is now the time to buy MRK? Find out in our full research report (it's free). Revenue: $15.53 billion vs analyst estimates of $15.29 billion (1.6% year-on-year decline, 1.6% beat) Adjusted EPS: $2.22 vs analyst estimates of $2.14 (3.8% beat) Adjusted EBITDA: $7.72 billion vs analyst estimates of $6.88 billion (49.7% margin, 12.2% beat) The company reconfirmed its revenue guidance for the full year of $64.85 billion at the midpoint Operating Margin: 37.8%, up from 35.7% in the same quarter last year Constant Currency Revenue rose 1% year on year (12% in the same quarter last year) Market Capitalization: $199.1 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Geoff Meacham (Citi): Asked how Merck plans to offset tariff headwinds. CEO Rob Davis explained supply chain restructuring and inventory management, emphasizing moves to 'U.S. for U.S.' manufacturing over price increases. Tim Anderson (Bank of America): Inquired about providing long-term guidance beyond KEYTRUDA's patent expiry. Davis reiterated confidence in the pipeline's potential but signaled no immediate plans for detailed long-term projections. Luisa Hector (Berenberg): Questioned the impact of FDA and HHS changes on vaccine approvals. Dr. Dean Li stated that near-term regulatory timelines remain on track, with no delays observed despite agency personnel transitions. Steve Scala (TD Cowen): Sought clarification on Gardasil's global growth outlook and long-term targets. CFO Caroline Litchfield noted the end of Japan's catch-up program and ongoing China headwinds, confirming the previous $11 billion Gardasil target has been withdrawn. Akash Tewari (Jefferies): Asked about the severity and impact of potential new tariffs. Davis declined to speculate on tariff rates but stressed Merck's preparedness through operational and manufacturing adjustments. In the coming quarters, the StockStory team will watch for (1) key data releases from late-phase clinical trials, especially in oncology and cardiovascular programs, (2) the impact of supply chain moves and tariff mitigation on cost structure, and (3) trends in Gardasil and other vaccine uptake outside China. Developments around regulatory filings and ACIP recommendations for vaccines will also be important markers to assess execution and pipeline momentum. Merck currently trades at $79.48, in line with $78.70 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio

Associated Press

40 minutes ago

• Associated Press

List of most expensive soccer signings in history

Florian Wirtz became one of the most expensive players in soccer history when the Germany playmaker joined Liverpool from Bayer Leverkusen on Friday for a fee of up to 116 million pounds ($156 million). Neymar: $262 million (222 million euros) Paris Saint-Germain shattered the world-record transfer fee by signing the Brazil superstar from Barcelona in August 2017. It was more than double the outlay of Manchester United to sign Paul Pogba from Juventus for $116 million a year earlier. It remains the record transfer fee. ___ Kylian Mbappé: $216 million (180 million euros) A few weeks after buying Neymar, PSG also secured a loan deal for Mbappé — then the rising star of French soccer playing for Monaco — that included the option to make the move permanent in 2018. PSG did so, making it an outlay of nearly $500 million on two players. ___ Philippe Coutinho: $192 million (160 million euros) Flush with cash after selling Neymar a year earlier, Barcelona spent most of it in a deal to buy Brazil playmaker Coutinho from Liverpool for a Spanish record fee. ___ Moises Caicedo: $146 million (115 million pounds) The Ecuador midfielder's move was previously the most expensive deal by a British club, with Chelsea buying him from Brighton in August 2023. ___ João Félix: $140 million (126 million euros) Atletico Madrid triggered a buyout clause in Félix's contract to sign the Portugal forward from Benfica in August 2019. ___ Jude Bellingham: $139 million (128.5 million euros) The England star got his big move to Real Madrid from Borussia Dortmund in June 2023, for an initial up-front fee of 103 million euros plus add-ons linked to performance. ___ Antoine Griezmann: $134 million (120 million euros) Atletico could afford to sign Félix after selling France forward Griezmann to Barcelona for a similar fee a few weeks earlier. ___ Neymar: $98 million (90 million euros) Outside from Europe, the biggest transfer deal also involved Neymar when he joined Al Hilal, a team in the Saudi Pro League, from Paris Saint-Germain in August 2023. That came at the height of Saudi Arabia's push to sign high-end soccer talent to ignite the oil-rich state's domestic league. ___ AP soccer:

New York Times

44 minutes ago

• New York Times

Former Liverpool, Newcastle striker Andy Carroll leaves Bordeaux ‘to return home'

Andy Carroll has left Girondins de Bordeaux after one season with the French club. Bordeaux confirmed the former Liverpool and Newcastle United striker had departed to 'return home' and be closer to his children. Carroll, 36, has spent the past two seasons in France having joined Ligue 2 side Amiens on a free transfer in September 2023. Advertisement After scoring four goals in 35 appearances for the second-tier side, the former England international joined National 2 outfit Bordeaux in the country's fourth tier. 'Andy brought his experience, physical impact, and professionalism to his role on a daily basis, both in the locker room and during important matches,' Bordeaux said in a statement. 'Off the pitch, he is an exceptional and generous personality that the club's fans and employees have enjoyed working alongside. 'Today, to be closer to his children, Andy has chosen to return home. We fully understand and respect this personal decision.' Carroll scored 11 goals in 23 matches for Bordeaux during the 2024-25 campaign as the six-time French champions recorded a fourth-placed finish. He joined the club in a particularly turbulent financial time, and was taking home a salary which was said to be extremely modest by professional football standards. 'I'm actually spending more money to be at Bordeaux than I am earning, basically,' Carroll told The Athletic in October. 'My rent is more than what I'm taking in. That's before eating, driving, flying. It was the same at Reading, where my apartment was more than my wages. I don't care about the money.' Bordeaux were initially demoted to Ligue 2 following a 20th-placed finish in the 2021-2022 season after being placed into administration. The club then suffered an administrative double relegation to National 2 last summer after not being able to provide financial guarantees ahead of the 2024-25 campaign. The Athletic reported in July 2024 that Liverpool owner Fenway Sports Group withdrew from talks to buy Bordeaux, with the club later filing for bankruptcy and losing their professional status. Carroll came through Newcastle's academy and after scoring 11 goals in the first half of the 2010-11 Premier League campaign, became Liverpool's record signing when he moved to Anfield for £35million on deadline day in January 2011. Advertisement He went on to score 11 goals in 58 matches for the Merseyside club before joining West Ham, where he would stay for seven years, recording 34 goals and 16 assists in 142 matches. Carroll re-joined Newcastle in 2019 and scored one goal in two seasons before moving to Reading, West Bromwich Albion, and then returning to Reading the following season.